186 related articles for article (PubMed ID: 14726402)
1. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
[TBL] [Abstract][Full Text] [Related]
2. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
[TBL] [Abstract][Full Text] [Related]
4. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
[TBL] [Abstract][Full Text] [Related]
5. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
[TBL] [Abstract][Full Text] [Related]
6. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.
Izbicka E; Campos D; Carrizales G; Patnaik A
Anticancer Res; 2005; 25(5):3215-23. PubMed ID: 16101130
[TBL] [Abstract][Full Text] [Related]
8. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M
Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
Santucci R; Mackley PA; Sebti S; Alsina M
Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
[TBL] [Abstract][Full Text] [Related]
11. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Gore L; Holden SN; Cohen RB; Morrow M; Pierson AS; O'Bryant CL; Persky M; Gustafson D; Mikule C; Zhang S; Palmer PA; Eckhardt SG
Ann Oncol; 2006 Nov; 17(11):1709-17. PubMed ID: 16980604
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes.
Nunes M; Shi C; Greenberger LM
Mol Cancer Ther; 2004 Jan; 3(1):21-7. PubMed ID: 14749472
[TBL] [Abstract][Full Text] [Related]
14. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway.
Reuveni H; Geiger T; Geiger B; Levitzki A
J Cell Biol; 2000 Dec; 151(6):1179-92. PubMed ID: 11121434
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
[TBL] [Abstract][Full Text] [Related]
16. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Thomas X; Elhamri M
Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
[TBL] [Abstract][Full Text] [Related]
17. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
[TBL] [Abstract][Full Text] [Related]
19. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]